APUS — Apimeds Pharmaceuticals US Balance Sheet
0.000.00%
Last trade - 00:00- $19.89m
- $20.51m
Annual balance sheet for Apimeds Pharmaceuticals US, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | 0.171 | 0.006 | 0.41 | 0.003 |
| Prepaid Expenses | ||||
| Total Current Assets | 0.172 | 0.006 | 0.422 | 0.013 |
| Total Assets | 0.172 | 0.006 | 0.422 | 0.013 |
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0.011 | 0.32 | 0.123 | 1.02 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Liabilities | 0.411 | 0.72 | 0.39 | 1.37 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | -0.238 | -0.714 | 0.032 | -1.36 |
| Total Liabilities & Shareholders' Equity | 0.172 | 0.006 | 0.422 | 0.013 |
| Total Common Shares Outstanding |